Pan Tumor Webinar Series: Evidence-based Updates on Checkpoint Inhibitors in the Metastatic Setting

When:  Aug 26, 2020 from 11:00 AM to 12:00 PM (ET)
Evidence-based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations

Presented by PlatformQ in collaboration with the Society for Immunotherapy of Cancer

Immunotherapy has permeated the cancer treatment landscape among several tumor types and treatment settings. With key late-stage clinical trials underway, immunotherapy experts provide critical updates on emerging data, recent approvals, and promising immunotherapy combinations with other classes of agents. Updates will be provided across solid tumors with opportunities to ask critical clinical questions and receive expert answers.


Featured Speakers:

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine, Chief of Medical Oncology, Associate Director for Translational Research
Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven

Brian I. Rini, MD
Chief of Clinical Trials
Vanderbilt-Ingram Cancer Center
Ingram Professor of Medicine
Vanderbilt University Medical Center

Topics of Interest:

  • Recent approvals
  • Key clinical trials
  • Monotherapy vs Emerging Combinations

Learning Objectives:

  • Examine the relevance of phase II and III trial data regarding emerging indications in solid tumors for immune checkpoint inhibitors
  • Assess latest clinical trial data on immune checkpoint inhibitors across a wide range of tumors and implement new practice standards accordingly
  • Recognize the rationale(s) behind combining checkpoint inhibitors with other anti-cancer drugs, including chemotherapy, targeted therapies, and other immunotherapy
  • Plan to effectively implement evidence-based new approaches of combination regimens with checkpoint inhibitors as they become available

Keywords:

Immunotherapy, monotherapy, combination immunotherapy, GU, GI, breast, gynecologic, lung, head and neck, HNC, SCCHN, CRC, clinical trials, radiotherapy, targeted therapy, skin cancer, melanoma, checkpoint inhibition

CME Information:

Immunotherapy Best Practices: Overcoming Clinical Challenges and Enhancing Treatment in Solid Tumors

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC in collaboration with the Society for Immunotherapy of Cancer.

ACKNOWLEDGEMENT
This activity is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation, Genentech, and Tesaro, A GSK Company.

TUITION
Complimentary


JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


CREDIT DESIGNATION STATEMENTS
Live Activity
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

June 10, 2020

  • 12:00pm – 1:00pm ET: Refining Patient Selection for Biomarker-Directed Immunotherapy

July 24, 2020

  • 12:00pm – 1:00pm ET: Optimizing Management of Adverse Events Associated with Immunotherapy
  • 1:00pm – 2:00pm ET: Life After Immunotherapy: Coordinating Care and Survivorship Plans

August 26, 2020

  • 12:00pm – 1:00pm ET: Evidence-Based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations

Enduring Material
The enduring material will be available from June 10, 2020 – February 28, 2021.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Refining Patient Selection for Biomarker-Directed Immunotherapy

  • Examine the variety of biomarkers associated with immune checkpoint inhibitor therapy
  • Select appropriate, evidence-based testing modalities for patients who are potential candidates for immune checkpoint inhibitor therapy and interpret testing results effectively

Optimizing Management of Adverse Events Associated with Immunotherapy

  • Anticipate unique and common immune-related adverse events associated with immunotherapy across a wide range of solid tumors
  • Implement expert-recommended best practices for managing adverse effects that can occur with immunotherapy

Life After Immunotherapy: Coordinating Care and Survivorship Plans

  • Apply recent guidelines and expert recommendations for the creation of comprehensive survivorship plans for patients who have received immune checkpoint inhibitors
  • Plan strategies on developing survivorship plans within your multidisciplinary cancer care team

Evidence-Based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations

  • Examine the relevance of phase II and III trial data regarding emerging indications in solid tumors for immune checkpoint inhibitors
  • Assess latest clinical trial data on immune checkpoint inhibitors across a wide range of tumors and implement new practice standards accordingly
  • Recognize the rationale(s) behind combining checkpoint inhibitors with other anti-cancer drugs, including chemotherapy, targeted therapies, and other immunotherapy
  • Plan to effectively implement evidence-based new approaches of combination regimens with checkpoint inhibitors as they become available

TARGET AUDIENCE
Medical, surgical, and radiation oncologists; primary care physicians; internal medicine specialists; health care professionals including oncology pharmacists, oncology advanced practice nurses and physician assistants, and other health care providers who participate in the care of patients with cancer.

ESTIMATED TIME TO COMPLETE
This activity consists of 1 session which should take approximately 1 hour to complete.


METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Reported Financial Relationship

Roy S. Herbst, MD, PhD

Consulting Fees: Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serrano, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Midas Health Analytics, Mirati Theraputics, Nektar, Neon Theraputics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen

Contracted Research: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company

Other: Junshi Pharmaceuticals

Brian I. Rini, MD

Consulting Fees: Merck, BMS, Pfizer, AVEO, Alkermes

Contracted Research: Merck, BMS, Genentech, AstraZeneca

 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner

Reported Financial Relationship

Tariqa Ackbarali

Medical Director

PlatformQ Health Education, LLC

None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Stone, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Media-Internet

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.